EUVIMEDEUVIMED entdecken
Multizentrische Studie

Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group

Noriyoshi Iriyama, Eisaku Iwanaga, Yuta Kimura, Naoki Watanabe, Maho Ishikawa, Hitomi Nakayama, Eriko Sato, Takayuki Tabayashi, Toru Mitsumori, Tomoiku Takaku, Tomonori Nakazato, Michihide Tokuhira und 4 weitere

International Journal of Hematology · 2024

DOI: 10.1007/s12185-024-03758-4 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Hematology, 2024. Verfasst von Noriyoshi Iriyama und 15 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kami-cho, Itabashi-ku, Tokyo, 173…. Hauptthemen laut MEDLINE: Protein Kinase Inhibitors, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Imatinib Mesylate. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 36 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study investigated changes in treatment modalities and outcomes of chronic myeloid leukemia in the chronic phase (CP-CML) after the approval of second-generation tyrosine kinase inhibitors (2G-TKIs) for first-line therapy. Patients were grouped into those who underwent TKI therapy up to December 2010 (imatinib era group, n = 185) and after January 2011 (2G-TKI era group, n = 425). All patients in the imatinib era group were initially treated with imatinib, whereas patients in the 2G-TKI era group were mostly treated with dasatinib (55%) or nilotinib (36%). However, outcomes including progression-free survival, overall survival, and CML-related death (CRD) did not differ significantly between groups. When stratified by risk scores, the prognostic performance of the ELTS score was superior to that of the Sokal score. Even though both scoring systems predicted CRD in the imatinib era, only the ELTS score predicted CRD in the 2G-TKI era. Notably, the outcome of patients classified as high-risk by ELTS score was more favorable in the 2G-TKI era group than in the imatinib era group. Thus, expanding treatment options may have improved patient outcomes in CP-CML, particularly in patients classified as high-risk by ELTS score.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Protein Kinase InhibitorsLeukemia, Myelogenous, Chronic, BCR-ABL PositiveImatinib MesylateHumansRetrospective StudiesMaleMiddle AgedFemaleAgedAdultTreatment OutcomeDasatinibAged, 80 and overPyrimidinesAdolescentYoung AdultPrognosisTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

Chronic myeloid leukemiaELTS scoreSokal scoreTreatment modalityTyrosine kinase inhibitor

Substanzen

Protein Kinase InhibitorsImatinib MesylateDasatinibPyrimidinesnilotinibTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Division of Hematology and Rheumatology, Department of Medicine, Nihon University School of Medicine, 30-1 Oyaguchi Kami-cho, Itabashi-ku, Tokyo, 173-8610, Japan. iriyama.noriyoshi@nihon-u.ac.jp.
  • Department of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan.
  • Department of Hematology, Japan Community Health Care Organization, Saitama Medical Center, Saitama, Japan.
  • Department of Hematology, Juntendo University School of Medicine, Tokyo, Japan.
  • Department of Hemato-Oncology, Saitama Medical University International Medical Center, Saitama, Japan.
  • Department of Hematology, Yokohama Municipal Citizen's Hospital, Yokohama, Japan.

Zitieren

APA

Iriyama, N., Iwanaga, E., Kimura, Y., Watanabe, N., Ishikawa, M., Nakayama, H., Sato, E., Tabayashi, T., Mitsumori, T., Takaku, T., Nakazato, T., Tokuhira, M., Fujita, H., Ando, M., Hatta, Y., & Kawaguchi, T. (2024). Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group. International Journal of Hematology. https://doi.org/10.1007/s12185-024-03758-4

Vancouver

Iriyama N, Iwanaga E, Kimura Y, Watanabe N, Ishikawa M, Nakayama H, et al. Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group. International Journal of Hematology. 2024. doi:10.1007/s12185-024-03758-4

BibTeX
@article{Iriyama2024,
  author = {Iriyama, Noriyoshi and Iwanaga, Eisaku and Kimura, Yuta and Watanabe, Naoki and Ishikawa, Maho and Nakayama, Hitomi and Sato, Eriko and Tabayashi, Takayuki and Mitsumori, Toru and Takaku, Tomoiku and Nakazato, Tomonori and Tokuhira, Michihide and Fujita, Hiroyuki and Ando, Miki and Hatta, Yoshihiro and Kawaguchi, Tatsuya},
  title = {Changes in chronic myeloid leukemia treatment modalities and outcomes after introduction of second-generation tyrosine kinase inhibitors as first-line therapy: a multi-institutional retrospective study by the CML Cooperative Study Group},
  journal = {International Journal of Hematology},
  year = {2024},
  doi = {10.1007/s12185-024-03758-4}
}
Kostenlos starten →